Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.76 EUR | -4.97% | +2.52% | -54.14% |
May. 14 | Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment | MT |
May. 14 | Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease | CI |
Sales 2024 * | 874M 950M | Sales 2025 * | 1.04B 1.13B | Capitalization | 1.73B 1.88B |
---|---|---|---|---|---|
Net income 2024 * | -29M -31.52M | Net income 2025 * | 34M 36.95M | EV / Sales 2024 * | 2.29 x |
Net Debt 2024 * | 269M 292M | Net Debt 2025 * | 235M 255M | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-58.8
x | P/E ratio 2025 * |
30.9
x | Employees | 5,061 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
1 day | -4.97% | ||
1 week | +2.52% | ||
Current month | +0.21% | ||
1 month | -27.43% | ||
3 months | -28.58% | ||
6 months | -47.78% | ||
Current year | -54.14% |
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-18 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 23-02-06 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 12-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-18 |
Roland Sackers
BRD | Director/Board Member | 56 | 19-06-18 |
Chairman | 63 | 14-06-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 17 M€ | -.--% | - | |
2.59% | 202 M€ | -.--% | ||
0.21% | 79 M€ | -.--% | ||
0.15% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 9.76 | -4.97% | 1,830,327 |
24-05-16 | 10.27 | -2.00% | 1,238,389 |
24-05-15 | 10.48 | +2.04% | 1,405,214 |
24-05-14 | 10.27 | +3.01% | 1,830,577 |
24-05-13 | 9.97 | +4.73% | 2,080,093 |
Delayed Quote Xetra, May 17, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.14% | 1.88B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- EVT Stock